700,000+ patients in the USA alone suffer from End Stage Renal Disease and millions more around the world.
ESRD treatment now costs Medicare over $100 billion per year for dialysis treatments and related patient services.
Over 850 million people on the planet live with some type of kidney disease.
37 million Americans suffer from chronic kidney disease.
In the US nearly 800,000 people suffer from kidney failure and need dialysis or a transplant
12% of COVID19 patients over 60 will develop AKI (acute kidney injury).
Covid patients with ESRD are 11 times more likely to end up in the hospital.
Severe shortage of donor kidneys.
Over 100,000 Americans are the kidney donor waiting list with waiting times of approximately 5 years.
1 in 3 adults who have diabetes also have CKD (chronic kidney disease)
US Kidney Research Corporation (formerly Curion Research Corporation), is a Delaware
C-Corp founded in June, 2015. For over 7 years, US Kidney Research Corporation has been involved in R&D of the world’s first waterless renal replacement technology.
Unlike standard dialysis, our new technology does not require purified water, dialysate concentrate solutions, or a dialyzer (disposables). For patients and technicians, whether in a home or clinical setting, it will simplify the entire blood purifying process. For providers, it will eliminate the massive water purifying infrastructure and the disposables needed for dialysis, saving enormous overhead costs. Additionally, billions of gallons of contaminated water created from dialysis and currently entering our drainage system would be eliminated, significantly reducing the negative impact on our environment.
Initially, our technology will be used to develop a portable artificial kidney. Ultimately, the same technology can be used in a standalone waterless renal therapy machine and implantable devices. US Kidney Research has an ongoing contract with the University of Arkansas to perform research under our guidance. The university was selected as their chief researchers are experts in the field of electrodeionization, which is the primary methodology used in our technology.
First in the world to create synthetic urine using a new blood purifying technology that involves filtration and ion transport processes similar to the native kidney. Animal studies were performed at Noble Life Sciences in Maryland using our latest prototype.
2021 - 650k award winner of the international KidneyX Phase 1 Artificial Kidney Contest for our novel development of a dialysate-free waterless portable and implantable artificial kidney technology
2019 - 75k award winner of KidneyX Redesign Dialysis Phase 1 contest sponsored in partnership by US Dept. of Health and Human Services and the American Society of Nephrology.
Invited as Guest speaker by International Federation for Artificial Organs (IFAO) to present at the American Society for Implantable Artificial Organs (ASAIO) Chicago conference in June 2020. We were invited again to speak in Washington DC in June 2021.
Interviewed twice by BioWorld Magazine; listed on GE Website (The Five Coolest Things on Earth - synthetic kidney); numerous online articles published about US Kidney Research Corporation
Science article published in Nature, the premier science journal in the world. "Simulating nephron ion transport function using activated wafer electrodeionization."
Nature Published Journal Article - "Could implantable artificial kidneys end the need for dialysis?"
US Patent - Granted 2021 - Patent No. US 10,933,184 B2
China Patent – Granted 2022 - CN111629813B
India Patent - Granted 2023 - Patent No. 419177
Japan Patent - Granted 2023 - Pate7213563
17 Unitary patent member countries in Europe - Granted August 2023
PCT international patents are filed in Singapore, S. Korea, Australia, UK, Spain, Canada, & Mexico.
Quality Management System ISO 13485:2016 for Medical Devices in place.
While developing our dialysis replacement technology, our primary research has led to other inventions:
1. New superior ultra-filter membrane material that can replace current materials used in dialyzers, the filter used to remove toxins during dialysis.
2. We are developing a new anti-coagulant coating that can be used to keep medical device tubing, blood testing equipment, and catheters from clotting. Also, anti-coagulant blood thinners given to patients prior to dialysis would no longer be needed.
3. Developing a new method using our technology to regenerate peritoneal dialysis solution in PD patients. Our technology will reduce the number of peritoneal solutions required by the industry resulting in significant cost savings.
Our revolutionary waterless technology for purifying the blood of patients with end stage kidney disease has the potential to completely replace current dialysis procedures in an industry that has not changed its methodology in decades. The technology is leading to a truly implantable artificial kidney. In collaboration with advisers and research scientists from two major universities, US Kidney Research Corporation has made significant progress in achieving its goals.
It is our intention to bring this new technology to clinical practice and help all those suffering from acute kidney injury(AKI) and end stage renal disease (ESRD).